• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

以患者为中心的真实世界证据的开发:共识过程中提出的新方法建议

Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process.

作者信息

Oehrlein Elisabeth M, Schoch Silke, Burcu Mehmet, McBeth Julia F, Bright Jennifer, Pashos Chris L, Willke Richard, Love T Rosie, Mattingly T Joseph, Perfetto Eleanor M

机构信息

National Health Council, Washington, DC, USA.

National Health Council, Washington, DC, USA.

出版信息

Value Health. 2023 Jan;26(1):28-38. doi: 10.1016/j.jval.2022.04.1738. Epub 2022 Jul 19.

DOI:10.1016/j.jval.2022.04.1738
PMID:35863944
Abstract

OBJECTIVES

The Joint ISPOR-ISPE Special Task Force on Real-World Evidence included patient/stakeholder engagement as a recommended good procedural practice when designing, conducting, and disseminating real-world evidence (RWE). However, there are no guidelines describing how patient experience data (PED) can be applied when designing real-world data (RWD) studies. This article describes development of consensus recommendations to guide researchers in applying PED to develop patient-centered RWE.

METHODS

A multidisciplinary advisory board, identified through recommendations of collaborators, was established to guide development of recommendations. Semistructured interviews were conducted to identify how experienced RWD researchers (n = 15) would apply PED when designing a hypothetical RWD study. Transcripts were analyzed and emerging themes developed into preliminary methods recommendations. An eDelphi survey (n = 26) was conducted to refine/develop consensus on the draft recommendations.

RESULTS

We identified 13 recommendations for incorporating PED throughout the design, conduct, and translation of RWE. The recommendations encompass themes related to the development of a patient-centered research question, designing a study, disseminating RWE, and general considerations. For example, consider how patient input can inform population/subgroups, comparators, and study period. Researchers can leverage existing information describing PED and may be able to apply those insights to studies relying on traditional RWD sources and/or patient registries.

CONCLUSIONS

Applying these emerging recommendations may improve the patient centricity of RWE through improved relevance of RWE to patient communities of interest and foster greater multidisciplinary participation and transparency in RWD research. As researchers gather experience by applying the methods recommendations, further refinement of these consensus recommendations may lead to "best practices."

摘要

目标

ISPOR - ISPE联合真实世界证据特别工作组将患者/利益相关者参与纳入设计、开展和传播真实世界证据(RWE)时推荐的良好程序实践。然而,尚无指南描述在设计真实世界数据(RWD)研究时如何应用患者体验数据(PED)。本文描述了共识性建议的制定过程,以指导研究人员应用PED来开发以患者为中心的RWE。

方法

通过合作者的推荐确定了一个多学科咨询委员会,以指导建议的制定。进行了半结构化访谈,以确定经验丰富的RWD研究人员(n = 15)在设计假设的RWD研究时将如何应用PED。对访谈记录进行了分析,并将新出现的主题发展为初步的方法建议。开展了一项电子德尔菲调查(n = 26),以完善/达成对建议草案的共识。

结果

我们确定了13条在RWE的整个设计、开展和转化过程中纳入PED的建议。这些建议涵盖了与以患者为中心的研究问题的制定、研究设计、RWE传播以及一般考虑相关的主题。例如,考虑患者的意见如何为研究人群/亚组、对照和研究周期提供信息。研究人员可以利用描述PED的现有信息,并可能能够将这些见解应用于依赖传统RWD来源和/或患者登记处的研究。

结论

应用这些新出现的建议可能会通过提高RWE与感兴趣的患者群体的相关性来改善RWE的以患者为中心程度,并促进RWD研究中更大程度的多学科参与和透明度。随着研究人员通过应用这些方法建议积累经验,对这些共识性建议的进一步完善可能会产生“最佳实践”。

相似文献

1
Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process.以患者为中心的真实世界证据的开发:共识过程中提出的新方法建议
Value Health. 2023 Jan;26(1):28-38. doi: 10.1016/j.jval.2022.04.1738. Epub 2022 Jul 19.
2
Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.治疗和/或比较效果的真实世界数据研究的良好实践:医疗保健决策中真实世界证据联合ISPOR-ISPE特别工作组的建议。
Value Health. 2017 Sep;20(8):1003-1008. doi: 10.1016/j.jval.2017.08.3019. Epub 2017 Sep 15.
3
Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.治疗和/或比较效果的真实世界数据研究的良好实践:ISPOR-ISPE联合特别工作组关于医疗保健决策中真实世界证据的建议。
Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1033-1039. doi: 10.1002/pds.4297.
4
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.提高透明度以建立对假设检验的真实世界二次数据研究的信任——原因、内容和方法:来自真实世界证据透明度倡议的建议和路线图。
Value Health. 2020 Sep;23(9):1128-1136. doi: 10.1016/j.jval.2020.04.002.
5
Enhancing Patient Centricity of Real-World Data Research: An Exploratory Analysis Using the Patient Experience Mapping Toolbox.增强真实世界数据研究的以患者为中心性:使用患者体验映射工具箱的探索性分析
Value Health. 2023 Jan;26(1):10-17. doi: 10.1016/j.jval.2022.10.002. Epub 2022 Dec 7.
6
Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.提高透明度以增强对用于假设检验的真实世界二次数据研究的信任——为何、是什么以及如何做:来自真实世界证据透明度倡议的建议和路线图
Pharmacoepidemiol Drug Saf. 2020 Nov;29(11):1504-1513. doi: 10.1002/pds.5079. Epub 2020 Sep 13.
7
Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings.最大化真实世界数据和真实世界证据的价值,加速中国医疗保健转型:外部顾问委员会会议总结。
Pharmaceut Med. 2024 May;38(3):157-166. doi: 10.1007/s40290-024-00520-3. Epub 2024 Apr 4.
8
Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.韩国药物生命周期监管决策中真实世界数据利用和真实世界证据生成的专家调查。
Clin Transl Sci. 2024 Apr;17(4):e13801. doi: 10.1111/cts.13801.
9
HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force.协调一致的方案模板,以提高评估治疗效果的真实世界证据研究假设再现性:国际药物经济学与结果研究学会/国际真实世界证据协会联合工作组的良好实践报告。
Value Health. 2022 Oct;25(10):1663-1672. doi: 10.1016/j.jval.2022.09.001.
10
Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.利用真实世界证据推动药物研发策略并为临床试验设计提供信息。
Clin Pharmacol Ther. 2022 Jan;111(1):77-89. doi: 10.1002/cpt.2480. Epub 2021 Nov 28.

引用本文的文献

1
Real-World Data Included in Post-authorisation Measures: A Case Study of Approved Advanced Therapy Medicinal Products in the European Union between 2013 and 2024.上市后措施中包含的真实世界数据:2013年至2024年欧盟批准的高级治疗药品案例研究
BioDrugs. 2025 Aug 26. doi: 10.1007/s40259-025-00737-x.
2
Patient Engagement and Patient Experience Data in Regulatory Review and Health Technology Assessment: Where Are We Today?监管审查和卫生技术评估中的患者参与度与患者体验数据:我们如今处于什么阶段?
Ther Innov Regul Sci. 2025 Apr 10. doi: 10.1007/s43441-025-00770-6.
3
Patient Experiences with the Impacts of Multiple Sclerosis & Disease-Modifying Therapies.
多发性硬化症及疾病修正治疗影响的患者体验
Clinicoecon Outcomes Res. 2025 Mar 15;17:199-215. doi: 10.2147/CEOR.S489929. eCollection 2025.
4
Co-creating tools for embedding meaningful patient and public involvement and engagement in real-world data and evidence research in the pharmaceutical industry setting: a multistakeholder participatory co-design study.共同创建工具,以在制药行业环境中切实将患者和公众参与及融入真实世界数据与证据研究:一项多利益相关方参与式协同设计研究
BMJ Open. 2025 Feb 17;15(2):e088914. doi: 10.1136/bmjopen-2024-088914.
5
An Access-Focused Patient-Centric Value Assessment Framework for Medication Formulary Decision-Making in Immune-Mediated Inflammatory Diseases.一种以免疫介导炎症性疾病药物处方集决策为重点的以患者为中心的价值评估框架。
Adv Ther. 2025 Feb;42(2):568-578. doi: 10.1007/s12325-024-03076-5. Epub 2024 Dec 20.
6
FOUNTAIN: a modular research platform for integrated real-world evidence generation.FOUNTAIN:一个用于生成综合真实世界证据的模块化研究平台。
BMC Med Res Methodol. 2024 Oct 1;24(1):224. doi: 10.1186/s12874-024-02344-w.
7
Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential.有前景的血液系统恶性肿瘤治疗策略:创新与潜力。
Molecules. 2024 Sep 9;29(17):4280. doi: 10.3390/molecules29174280.
8
Cost-effectiveness of robotic vs laparoscopic distal pancreatectomy. Results from the national prospective trial ROBOCOSTES.机器人辅助与腹腔镜辅助胰体尾切除术的成本效益比较。ROBOCOSTES 全国前瞻性试验结果。
Surg Endosc. 2024 Nov;38(11):6270-6281. doi: 10.1007/s00464-024-11109-x. Epub 2024 Aug 13.
9
A rare partnership: patient community and industry collaboration to shape the impact of real-world evidence on the rare disease ecosystem.一种罕见的合作关系:患者群体与行业合作,共同塑造真实世界证据对罕见病生态系统的影响。
Orphanet J Rare Dis. 2024 Jul 10;19(1):262. doi: 10.1186/s13023-024-03262-2.
10
Scoping review of the recommendations and guidance for improving the quality of rare disease registries.罕见病登记处质量改进建议和指南的范围综述。
Orphanet J Rare Dis. 2024 May 6;19(1):187. doi: 10.1186/s13023-024-03193-y.